Cargando…
硼替佐米、利妥昔单抗、环磷酰胺、阿霉素和泼尼松（VR-CAP）方案治疗初治套细胞淋巴瘤60例的疗效及预后分析
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Editorial office of Chinese Journal of Hematology
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293007/ https://www.ncbi.nlm.nih.gov/pubmed/34218585 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2021.05.011 |
| _version_ | 1783724936597078016 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8293007 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Editorial office of Chinese Journal of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-82930072021-08-23 硼替佐米、利妥昔单抗、环磷酰胺、阿霉素和泼尼松（VR-CAP）方案治疗初治套细胞淋巴瘤60例的疗效及预后分析 Zhonghua Xue Ye Xue Za Zhi 短篇论著 Editorial office of Chinese Journal of Hematology 2021-05 /pmc/articles/PMC8293007/ /pubmed/34218585 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2021.05.011 Text en 2021年版权归中华医学会所有 https://creativecommons.org/licenses/by/3.0/This work is licensed under a Creative Commons Attribution 3.0 License. |
| spellingShingle | 短篇论著 硼替佐米、利妥昔单抗、环磷酰胺、阿霉素和泼尼松（VR-CAP）方案治疗初治套细胞淋巴瘤60例的疗效及预后分析 |
| title | 硼替佐米、利妥昔单抗、环磷酰胺、阿霉素和泼尼松（VR-CAP）方案治疗初治套细胞淋巴瘤60例的疗效及预后分析 |
| title_full | 硼替佐米、利妥昔单抗、环磷酰胺、阿霉素和泼尼松（VR-CAP）方案治疗初治套细胞淋巴瘤60例的疗效及预后分析 |
| title_fullStr | 硼替佐米、利妥昔单抗、环磷酰胺、阿霉素和泼尼松（VR-CAP）方案治疗初治套细胞淋巴瘤60例的疗效及预后分析 |
| title_full_unstemmed | 硼替佐米、利妥昔单抗、环磷酰胺、阿霉素和泼尼松（VR-CAP）方案治疗初治套细胞淋巴瘤60例的疗效及预后分析 |
| title_short | 硼替佐米、利妥昔单抗、环磷酰胺、阿霉素和泼尼松（VR-CAP）方案治疗初治套细胞淋巴瘤60例的疗效及预后分析 |
| title_sort | 硼替佐米、利妥昔单抗、环磷酰胺、阿霉素和泼尼松（vr-cap）方案治疗初治套细胞淋巴瘤60例的疗效及预后分析 |
| topic | 短篇论著 |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293007/ https://www.ncbi.nlm.nih.gov/pubmed/34218585 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2021.05.011 |
| work_keys_str_mv | AT péngtìzuǒmǐlìtuǒxīdānkànghuánlínxiānànāméisùhépōnísōngvrcapfāngànzhìliáochūzhìtàoxìbāolínbāliú60lìdeliáoxiàojíyùhòufēnxī AT péngtìzuǒmǐlìtuǒxīdānkànghuánlínxiānànāméisùhépōnísōngvrcapfāngànzhìliáochūzhìtàoxìbāolínbāliú60lìdeliáoxiàojíyùhòufēnxī AT péngtìzuǒmǐlìtuǒxīdānkànghuánlínxiānànāméisùhépōnísōngvrcapfāngànzhìliáochūzhìtàoxìbāolínbāliú60lìdeliáoxiàojíyùhòufēnxī AT péngtìzuǒmǐlìtuǒxīdānkànghuánlínxiānànāméisùhépōnísōngvrcapfāngànzhìliáochūzhìtàoxìbāolínbāliú60lìdeliáoxiàojíyùhòufēnxī AT péngtìzuǒmǐlìtuǒxīdānkànghuánlínxiānànāméisùhépōnísōngvrcapfāngànzhìliáochūzhìtàoxìbāolínbāliú60lìdeliáoxiàojíyùhòufēnxī AT péngtìzuǒmǐlìtuǒxīdānkànghuánlínxiānànāméisùhépōnísōngvrcapfāngànzhìliáochūzhìtàoxìbāolínbāliú60lìdeliáoxiàojíyùhòufēnxī AT péngtìzuǒmǐlìtuǒxīdānkànghuánlínxiānànāméisùhépōnísōngvrcapfāngànzhìliáochūzhìtàoxìbāolínbāliú60lìdeliáoxiàojíyùhòufēnxī |